5:43 PM
May 20, 2014
 |  BC Extra  |  Company News

Celgene licenses nab-rapamycin to AADi

Celgene Corp. (NASDAQ:CELG) granted AADi LLC (Pacific Palisades, Calif.) an exclusive, worldwide license to develop and commercialize Celgene's ABI-009, a nanoparticle albumin-bound (nab) formulation of rapamycin, also known as sirolimus. Financial terms are...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >